Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

Rice University researchers reported promising results from the first human trial of an implantable cancer immunotherapy designed to fight tumors while reducing side effects. Photo via Unsplash

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

From Your Site Articles

Motif Neurotech is developing minimally invasive bioelectronics to treat psychiatric conditions. Photo via motifneuro.tech

Houston startup’s brain implant for depression advances to clinical trial

moving forward

Houston-based Motif Neurotech has received FDA approval to move forward with its first clinical trial for its innovative way to fight treatment-resistant depression and other mental health disorders.

The company has developed a brain-computer interface technology based on research from Rice University. The blueberry-sized, wirelessly powered implantable device known as the Digitally-programmable Over-brain Therapeutic (DOT) stimulator delivers electrical stimulation to brain circuits linked to depression. The DOT stimulator sits in the skull above the dura without touching the brain and is considered an alternative to transcranial magnetic stimulation, which requires multiple treatment sessions and can cause headaches.

“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Jacob Robinson, a Rice University professor of electrical computer engineering and bioengineering and CEO of Motif Neurotech, said in a news release. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.”

Eligible adults whose depression has not improved after trying multiple therapies can take part in the study. The clinical trial will be conducted in collaboration with Baylor College of Medicine, Brain Health Consultants (Houston), UT Health Houston, Massachusetts General Brigham, Emory Healthcare, University of Iowa, University of Utah Health and New York University, according to Rice.

Motif also announced that it was one of the first teams selected for ARPA-H’s EVIDENT initiative, which recently awarded up to $139.4 million to spur new, effective therapies for behavioral health. Through the initiative, Motif will collect additional data alongside its clinical trial.

“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson added in the release.

Motif Neurotech was spun out of Robinson’s and Professor Kaiyuan Yang’s labs at Rice, along with collaborators and co-founders Dr. Sameer Sheth at Baylor College of Medicine and Dr. Sunil Sheth at the University of Texas Health Science Center at Houston. It was founded through the Rice Biotech Launch Pad. The company closed its Series A round with an oversubscribed $18.75 million last year.

A new deal will give tech giant Intel the option to evaluate specific Rice-patented technologies. Photo via Rice University.

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

The Rice Biotech Launch Pad has named two bioengineering professors to its leadership team. Photo courtesy Rice University.

Rice biotech accelerator appoints 2 leading researchers to team

Launch Pad

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team.

Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator, according to Rice.

“Their deep understanding of both the scientific rigor required for successful innovation and the commercial strategies necessary to bring these technologies to market will be invaluable as we continue to build our portfolio of lifesaving medical technologies,” Omid Veiseh, faculty director of the Launch Pad, said in a news release.

Amanda Nash

Nash leads a research program focused on developing cell communication technologies to treat cancer, autoimmune diseases and aging. She previously trained as a management consultant at McKinsey & Co., where she specialized in business development, portfolio strategy and operational excellence for pharmaceutical and medtech companies. She earned her doctorate in bioengineering from Rice and helped develop implantable cytokine factories for the treatment of ovarian cancer. She holds a bachelor’s degree in biomedical engineering from the University of Houston.

“Returning to Rice represents a full-circle moment in my career, from conducting my doctoral research here to gaining strategic insights at McKinsey and now bringing that combined perspective back to advance Houston’s biotech ecosystem,” Nash said in the release. “The Launch Pad represents exactly the kind of translational bridge our industry needs. I look forward to helping researchers navigate the complex path from discovery to commercialization.”

Kelsey L. Swingle

Swingle’s research focuses on engineering lipid-based nanoparticle technologies for drug delivery to reproductive tissues, which includes the placenta. She completed her doctorate in bioengineering at the University of Pennsylvania, where she developed novel mRNA lipid nanoparticles for the treatment of preeclampsia. She received her bachelor’s degree in biomedical engineering from Case Western Reserve University and is a National Science Foundation Graduate Research Fellow.

“What draws me to the Rice Biotech Launch Pad is its commitment to addressing the most pressing unmet medical needs,” Swingle added in the release. “My research in women’s health has shown me how innovation at the intersection of biomaterials and medicine can tackle challenges that have been overlooked for far too long. I am thrilled to join a team that shares this vision of designing cutting-edge technologies to create meaningful impact for underserved patient populations.”

The Rice Biotech Launch Pad opened in 2023. It held the official launch and lab opening of RBL LLC, a biotech venture creation studio in May. Read more here.

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. Photo via motifneuro.tech

Houston mental health tech startup receives industry validation for bioelectronic device

on the right path

A new tool in the fight against treatment-resistant depression could be on the horizon thanks to a Rice University professor.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering is also co-founder and CEO of Motif Neurotech. Created through the Rice Biotech Launch Pad, Motif Neurotech is focused on developing minimally invasive bioelectronics for the treatment of psychiatric conditions. The company closed its series A round with an oversubscribed $18.75 million earlier this year.

This week, Rice University announced that Robinson has published a peer-reviewed study in Science Advances describing his wireless device called the Digitally programmable Over-brain Therapeutic (DOT). The epidural cortical stimulator is 9 millimeters in width, meaning that it’s easily implantable but is powerful enough to send electrical stimulation to the brain through the dura, the membrane that protects the brain and spinal cord.

“It overcomes challenges by using a battery-free and wireless approach to create an implant that can deliver precise and programmable stimulation to the brain, without brain surgery,” Robinson explained in a press release.

Jacob Robinson, a professor of electrical and computer engineering and of bioengineering, is also co-founder and CEO of Motif Neurotech. Photo via motifneuro.tech

The DOT stimulator is intended to send electrical charges meant to provide neuromodulation for mental health woes including not just depression, but also obsessive compulsive disorder and post-traumatic stress disorder. The treatment could be an alternative to transcranial magnetic stimulation (TMS), a technique that has increased in popularity in recent years.

TMS uses pulsed magnetic fields to stimulate the brain. A typical TMS course includes 36 total treatments and can cause headaches. The DOT stimulator can enact the same timing patterns used in TMS, such as the intermittent theta burst stimulation (iTBS) paradigm, which has been noted to improve mood in patients, but can be achieved at home with far greater ease. Implantation takes just 20 minutes.

So far, the DOT stimulator has been implanted in both a human and a pig. In the pig, researchers noted that the electrical stimulation did not cause any damage to the brain or dura. Just as importantly, it showed stable performance for 30 days in inducing motor responses, meaning it can operate on a longer-term basis.

Motif Neurotech was founded along with Kaiyuan Yang and physicians Sunil Sheth and Sameer Sheth. The Rice Biotech Launchpad brings together local researchers like Robinson and his team with a network of industry executives. With their manuscript, entitled “Miniature battery-free epidural cortical stimulators” freshly published on the Science Advances website, big things could be coming for the bioelectronics company and for sufferers of treatment-resistant depression.

Rice team demonstrates miniature brain stimulator in humanswww.youtube.com

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-area NASA contractor plans Nasdaq IPO

going public

Webster-based NASA contractor Rothe Development Inc. has filed paperwork with the U.S. Securities and Exchange Commission to go public.

Rothe, a minority- and woman-owned business, hasn’t yet identified how many shares it will sell and how much money its IPO might raise. Rothe plans to offer Class B common stock on the Nasdaq exchange.

CEO Karen Wheeler-Hall owns all of the Class A shares and would retain majority control after the IPO, according to the SEC filing. The company plans to use $2.4 million of the IPO proceeds so Wheeler-Hall can pay off a loan from the seller for her 2021 acquisition of Rothe.

From last December to this May, the company raised about $2.1 million in a pre-IPO private placement at $1 per share, the SEC filing shows.

Rothe runs NASA training lab in Houston

Founded in 1967, Rothe supplies engineering, technology, operations and technical services to NASA, the U.S. Department of Defense, other federal agencies, commercial space operators, and regulated industries.

Rothe is likely best known for operating NASA’s Neutral Buoyancy Laboratory in Houston. The lab trains astronauts for spacewalks and simulates space missions. It supports NASA’s International Space Station and Artemis programs.

Company sees room for growth

In the SEC filing, Rothe said it operates in several expanding markets driven by rising investments, including space exploration, national security, cybersecurity and digital infrastructure.

“We believe these market trends create significant opportunities for continued growth across both government and commercial sectors,” the company said.

Rothe generated nearly $126.4 million in revenue last year, up from $117.3 million the previous year. However, the company swung to a $700,000 operating loss in 2025 versus $1.8 million in operating income in 2024.

At the end of 2025, Rothe’s workforce comprised 385 employees and 25 subcontractors. The company also works in the cybersecurity, computer engineering, software development, multimedia and communication, and commercial calibration sectors, according to its website.

Houston university ranks No. 10 best in the U.S. in new 2027 report

Rice Ranking

Education ranking and review website Niche has released its 2027 rankings of the best colleges in the U.S., and Rice University leads as the No. 1 best university in Texas, and No. 10 best nationwide.

Niche's annual rankings compared over 4,000 colleges and universities based on their academics, value, student life, career preparation, and more. Schools receive letter grades across 14 metrics, which were expanded this year to include Student Wellness and Future Readiness.

Also new to this year's rankings, Niche implemented an "Institutional Success Score" that "places every college into one of 10 mission-based categories" and compared each school against "outcomes aligned with that mission," which included research institutions, social mobility-focused colleges, and religious institutions, among others.

Rice University ranked 10th in three national lists: Best Colleges in America, Top Private Universities, and Colleges with the Best Professors.

Rice also received the following top-100 rankings:

No. 11 – Most Diverse Colleges
No. 14 – Best College Campuses
No. 15 – Colleges With the Best Academics
No. 20 – Colleges With the Best Student Life
No. 23 – Hardest Colleges To Get Into
No. 27 – Best Colleges for Student Athletes
No. 69 – Best College Dorms
No. 70 – Best Value Colleges
No. 74 – Best College Locations
No. 89 – Best College Food

On the local front, University of Houston and two of its branch campuses also ranked among the top 20 best universities in Texas. UH ranked a respectable No. 7 in the statewide list, and it ranked as the 123rd best university in the U.S. It fared better in the nationwide list of the Best Big Colleges, appearing at No. 53, and ranked 54th in Niche's Top Public Universities list.

The University of Houston-Clear Lake branch ranked as the 11th best Texas university and came in at No. 192 overall. It's the 33rd Best Hispanic Serving Institution (HSI), the 69th Best Value College, and it ranked 89th in the Top Public Universities list.

University of Houston Downtown is the 13th Best Online College in America, the 15th best university in Texas, and it's the 49th Best HSI in America. In the overall list of the best universities, UHD ranked 231st.Top education institutions across Texas

Three other Texas universities outside Houston excelled on Niche's list of the 100 Best Colleges in America.

The University of Texas at Austin ranked second statewide and 30th nationwide, and topped the list of Colleges With the Best Student Life. UT Austin also racked up top-10 acclaim in the separate lists of the Best College Locations (No. 4), Top Public Universities (No. 5), Best Big Colleges (No. 6), Best College Campuses (No. 10), and Best Colleges For Student Athletes (No. 10).

Texas A&M University in College Station and Trinity University in San Antonio round out the remaining Texas institutions that ranked among the top 100 overall. The Aggies ranked 52nd nationwide, and the Trinity Tigers ranked 65th overall.

---

This article originally appeared on CultureMap.com.

10 can't-miss events at Houston Energy and Climate Week 2026

HECW lineup

Editor's note: Houston Energy and Climate Week returns for its third year, Sept. 12–18, with panels, happy hours, pitch days and tours focused on the energy transition.

The Ion District will host many of the week's events. Here are details on some can't-miss, signature events and how to register. Find the full schedule here. Please note: this article may be updated to add more events.

Sept. 13 — The & Awards

Kick off the week by celebrating Houston honorees leading the future of energy at the & Awards. The & Awards will honor Zay Zeidman, chairman of Houston First and managing partner of Altitude Ventures; The University of Houston's Renu Khator and Ramanan Krishnamoorti; Maryanne Maldonado, CEO of the World Affairs Council; and Fervo Energy co-founders Tim Latimer (CEO) and Jack Norbeck (CTO). The inaugural posthumous Lifetime Ambassador Award will honor former Houston Mayor Sylvester Turner, and this year’s Allies in Energy grant recipients will also be recognized. The evening will include a fireside chat, an immersive gallery, live music, passed hors d'oeuvres, Champagne and plenty of networking opportunities.

This event is Sunday, Sept. 13, from 6-9 p.m. at ARTECHOUSE Houston. Register here.

Sept. 14 — Brews on the Bayou

Head to Saint Arnold Brewery for a more laid-back kickoff event. Grab a beer and take in a live conversation with Paul Hobby, managing director of Genesis Park, and Katie Mehnert, CEO of The Bee Suite and co-founder of HECW. Rice University's Aaron Pomerantz will moderate the discussion. Then hear a live performance from AY Young.

This event is Monday, Sept. 14, from 6-9 p.m. at Saint Arnold Brewery. Register here.

Sept. 14–18 — Sip For Sustainability

Enjoy a signature cocktail at five H Town Restaurant Group spots each night of Houston Energy and Climate Week. A portion of every purchase will go toward Allies in Energy, which supports education, collaboration, and community programs that drive a more sustainable future. Participating eateries include Hugo's, Xochi, Uber, Zaranda and Caracol.

These events begin Monday, Sept. 14, from 3-5 p.m. Find more information on each day's happy hour here.

Sept. 15 — HTX Tech Tours

HECW will present two Tech Tours this year, offering attendees a closer look at the region's climatech scene. The Metro Innovation Tour & Market will visit Sugar Land Town Square, Shell Technology Center Houston, SLB West Houston Campus, University of Houston at Sugar Land, Ambrosia Space, NanoTech Materials and Syzygy Plasmonics. The Bay City South Innovation Tour will visit Sugar Land Town Square and Erthos Project Bravo in Matagorda County. Both tours will head to Astros Night at Daikin Park to wrap up the day.

These events are Tuesday, Sept. 15. Find more information here.

Sept. 15 — Meet the Activate Houston Cohort 2026 Fellows

Meet Activate's latest cohort, which was named this summer, and learn more about their hardtech and climate-focused solutions. Also meet founders from the organization’s 2025 cohort during Houston Energy and Climate Startup Week.

This event is Tuesday, Sept. 15, from 5-7 p.m. at the Ion. Register here.

Sept. 15 – Cypher Pilotathon and Startup Showcase

Grab coffee and take in keynotes and panels featuring leaders from Amperon, Aramco Ventures, New Climate Ventures, Syzygy Plasmonics and many others during this signature event, this year under the theme “The NEW Energy Industrial Revolution.” After lunch, hear pitches from 31 ventures during the Pilotathon. This year's event will also feature a startup showcase with interactive booths where attendees can meet founders and see demonstrations, plus an industry hub where corporates and investors can engage with emerging technologies and identify the pilots they want to move forward with.

This event is Tuesday, Sept. 15, from 9 a.m.-5 p.m. at POST Houston. Get tickets here.

Sept. 15 — Houston Astros Energy Night

Catch a game and chat with fellow clean energy enthusiasts during Houston Astros Energy Night. The 'Stros take on the Kansas City Royals. A bonus? Dollar Hot Dog Night at Daikin Park.

This event is Tuesday, Sept. 15, starting at 7:10 p.m. at Daikin Park. Get tickets here.

Sept. 16 — Greentown Labs Climatech Summit

Entrepreneurs, investors, corporate leaders, policymakers and philanthropists will head to Houston this month for the annual Greentown Climatetech Summit. Hear from Greentown CEO Georgina Campbell Flatter and keynote speaker Tim Latimer, CEO and co-founder of Houston geothermal unicorn Fervo Energy, plus numerous other engaging panels at the Ion. Then head to Greentown Labs for an open house and startup showcase, where attendees can meet some of the climatech incubators' members, before taking in the startup pitch competition followed by happy hour over at the Continental Club.

This event is Wednesday, Sept. 16, from 8 a.m.–9 p.m. at multiple locations. Register here.

Sept. 17 — Rice Alliance Energy Tech Venture Forum

Hear from clean energy startups from around the world at the 23rd annual Energy Tech Venture Forum. In addition to the pitches, this event will also host keynotes from Sean Maher, chief economist at Phillips 66, and Ira Ehrenpreis, founder and managing partner of DBL Partner. Panels will focus on technologies, infrastructure and commercialization strategies needed to deploy breakthrough innovations at scale. Following the event, the Rice Alliance will also name its annual “Most Promising” startup.

This event is Thursday, Sept. 17, from 7:30 a.m.-5 p.m. at Rice University’s Jones Graduate School of Business. Register here.

Sept. 18 — Halliburton Labs Finalists Pitch Day

Hear from Halliburton Labs' latest cohort of entrepreneurs. The incubator aims to advance the companies’ commercialization with support from Halliburton's network, facilities and financing opportunities. Its latest cohort includes one company from Texas.

This event is Friday, Sept. 18, from 8 a.m.-noon at The Ion. Register here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME